Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV

Journal of Clinical Virology

Volumn 22, Issue 1, 2001, Pages 11-29

  Arens, M ^a  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

Drug resistance analysis; Sequence based genotyping; Viral type and subtype analysis

Indexed keywords

ABACAVIR; ALPHA INTERFERON; AMPRENAVIR; ANTIVIRUS AGENT; CIDOFOVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RIBAVIRIN; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG RESISTANCE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS;

EID: 0034971533     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(01)00156-1     Document Type: Article

References (62)

1. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group
2. Methods for subtyping and molecular comparison of human viral genomes
3. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
4. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
5. Pathogenesis, diagnosis and management of hepatitis C
6. Utility of early testing for HCV viremia as predictive factor of sustained response during interferon or interferon plus ribavirin treatment
7. DNA microarrays of the complex human cytomegalovirus genome: profiling kinetic class with drug sensitivity of viral gene expression
8. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance
9. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
10. Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS
11. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes
12. Lamivudine as initial treatment for chronic hepatitis B in the United States
13. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues
14. Antiviral susceptibility testing
15. Resistance of human cytomegalovirus to antiviral drugs
16. Hepatitis B virus genotypic resistance to lamivudine letter
17. Hepadnaviridae and their replication
18. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test
19. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure
20. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir
21. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel
22. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel
23. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
24. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells
25. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
26. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
27. Rapid and sensitive genotyping of hepatitis C virus by single-strand conformation polymorphism
28. Comparison of DNA enzyme immunoassay and line probe assays (Inno-LiPA HCV I and II) for hepatitis C virus genotyping
29. Hepatitis B virus infection
30. Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis
31. Genotypes and genetic variation of hepatitis C virus
32. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection
33. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
34. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
35. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group
36. Clinical significance of hepatitis C virus genotypes
37. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
38. Lamivudine-resistant human immunodeficiency virus type 1 variants 184V require multiple amino acid changes to become co-resistant to zidovudine in vivo
39. New cleavase fragment length polymorphism method improves the mutation detection assay
40. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group IHIT
41. Is an a la carte combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group
42. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation
43. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy
44. DNA sequencing with chain-terminating inhibitors
45. Herpes simplex virus type 2 meningitis in the absence of genital lesions: improved recognition with use of the polymerase chain reaction
46. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase
47. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
48. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir
49. Application of long PCR method of identification of variations in nucleotide sequences among varicella-zoster virus isolates
50. Hepatitis B virus HBV mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus
51. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
52. Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh 11a genetic groups
53. Famciclovir in chronic hepatitis B: results of a dose-finding study
54. Prevalence of Mutations Associated with Reduced Antiretroviral Drug Susceptibility among Human Immunodeficiency Virus Type 1 Seroconverters in the United States, 1993-1998
55. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma
56. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene [letter]
57. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance
58. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences
59. A practical approach to genetic screening for influenza virus variants
60. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy